1. Home
  2. FTAI vs RPRX Comparison

FTAI vs RPRX Comparison

Compare FTAI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FTAI

FTAI Aviation Ltd.

HOLD

Current Price

$250.17

Market Cap

26.0B

Sector

Industrials

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$55.07

Market Cap

22.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTAI
RPRX
Founded
2011
1996
Country
United States
United States
Employees
985
N/A
Industry
Misc Corporate Leasing Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.0B
22.0B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FTAI
RPRX
Price
$250.17
$55.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$274.67
$51.40
AVG Volume (30 Days)
1.0M
3.2M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
0.75%
1.90%
EPS Growth
N/A
N/A
EPS
N/A
0.67
Revenue
N/A
$2,378,193,000.00
Revenue This Year
$32.73
$38.63
Revenue Next Year
$51.41
$4.73
P/E Ratio
$65.85
$82.04
Revenue Growth
N/A
5.06
52 Week Low
$109.90
$33.37
52 Week High
$323.51
$55.86

Technical Indicators

Market Signals
Indicator
FTAI
RPRX
Relative Strength Index (RSI) 50.80 65.22
Support Level $216.34 $35.35
Resistance Level $261.25 N/A
Average True Range (ATR) 13.61 1.16
MACD -0.10 0.01
Stochastic Oscillator 75.24 78.31

Price Performance

Historical Comparison
FTAI
RPRX

About FTAI FTAI Aviation Ltd.

FTAI Aviation Ltd is an independent engine maintenance platform focused on the CFM56-5B, CFM56-7B, and V2500 aircraft engines, which power the 737NG and A320ceo aircraft. The company repairs and rebuilds engines in its maintenance facilities and with joint venture partners, and sells or leases engines through its proprietary Maintenance, Repair and Exchange (MRE) model under the Aerospace Products segment, which earns maximum revenue from North America and develops, repairs/refurbishes, and sells aircraft engines and aftermarket components. It also operates an Aviation Leasing segment, owning and managing a portfolio of on- and off-lease aircraft and engines, including engine transfers for rebuilding and sales.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: